Literature DB >> 8644717

Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City.

M X Tang1, G Maestre, W Y Tsai, X H Liu, L Feng, W Y Chung, M Chun, P Schofield, Y Stern, B Tycko, R Mayeux.   

Abstract

Apolipoprotein-E epsilon 4 (APOE-epsilon 4) has been consistently associated with Alzheimer disease (AD) and may be responsible for an earlier age at onset. We have previously reported a diminished association between APOE-epsilon 4 and AD in African Americans. Using a new method, which allows inclusion of censored information, we compared relative risks by APOE genotypes in an expanded collection of cases and controls from three ethnic groups in a New York community. The relative risk for AD associated with APOE-epsilon 4 homozygosity was increased in all ethnic groups (African American relative risk [RR]=3.0; 95% confidence interval [CI]=1.5-5.9; Caucasian RR=7.3, 95% CI=2.5-21.6; and Hispanic RR=2.5, 95% CI=1.1-5.7), compared with those with APOE-epsilon 3/epsilon 3 genotypes. The risk was also increased for APOE-epsilon 4 heterozygous Caucasians (RR=2.9, 95% CI=1.7-5.1) and Hispanics (RR=1.6, 95% CI=1.1-2.3), but not for African Americans (RR=0.6, 95% Ci=0.4-0.9). The age distribution of the proportion of Caucasians and Hispanics without AD was consistently lower for APOE-epsilon 4 homozygous and APOE-epsilon 4 heterozygous individuals than for those with other APOE genotypes. In African Americans this relationship was observed only in APOE-epsilon 4 homozygotes. These results confirm that APOE genotypes influence the RR of AD in Caucasians and Hispanics. Differences in risk among APOE-epsilon 4 heterozygote African Americans suggest that other genetic or environmental factors may modify the effect of APOE-epsilon 4 in some populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644717      PMCID: PMC1914582     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  46 in total

1.  Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks.

Authors:  G Maestre; R Ottman; Y Stern; B Gurland; M Chun; M X Tang; M Shelanski; B Tycko; R Mayeux
Journal:  Ann Neurol       Date:  1995-02       Impact factor: 10.422

2.  Alzheimer's disease, apolipoprotein E4, and gender.

Authors:  H Payami; K R Montee; J A Kaye; T D Bird; C E Yu; E M Wijsman; G D Schellenberg
Journal:  JAMA       Date:  1994-05-04       Impact factor: 56.272

3.  Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men.

Authors:  J H Stengård; K E Zerba; J Pekkanen; C Ehnholm; A Nissinen; C F Sing
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

4.  Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study.

Authors:  P W Wilson; R H Myers; M G Larson; J M Ordovas; P A Wolf; E J Schaefer
Journal:  JAMA       Date:  1994-12-07       Impact factor: 56.272

5.  The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival.

Authors:  C M van Duijn; P de Knijff; A Wehnert; J De Voecht; J B Bronzova; L M Havekes; A Hofman; C Van Broeckhoven
Journal:  Ann Neurol       Date:  1995-05       Impact factor: 10.422

6.  Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study.

Authors:  J Kuusisto; K Koivisto; K Kervinen; L Mykkänen; E L Helkala; M Vanhanen; T Hänninen; K Pyörälä; Y A Kesäniemi; P Riekkinen
Journal:  BMJ       Date:  1994-09-10

7.  Age-specific incidence of Alzheimer's disease in a community population.

Authors:  L E Hebert; P A Scherr; L A Beckett; M S Albert; D M Pilgrim; M J Chown; H H Funkenstein; D A Evans
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

8.  Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans.

Authors:  H C Hendrie; K S Hall; S Hui; F W Unverzagt; C E Yu; D K Lahiri; A Sahota; M Farlow; B Musick; C A Class
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

9.  High frequency of the apo epsilon 4 allele in Khoi San from South Africa.

Authors:  C Sandholzer; R Delport; H Vermaak; G Utermann
Journal:  Hum Genet       Date:  1995-01       Impact factor: 4.132

10.  ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease.

Authors:  S Sorbi; B Nacmias; P Forleo; S Latorraca; I Gobbini; L Bracco; S Piacentini; L Amaducci
Journal:  Neurosci Lett       Date:  1994-08-15       Impact factor: 3.046

View more
  55 in total

Review 1.  Candidate gene case-control association studies: advantages and potential pitfalls.

Authors:  A K Daly; C P Day
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 2.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

4.  Food insecurity and cognitive function in Puerto Rican adults.

Authors:  Xiang Gao; Tammy Scott; Luis M Falcon; Parke E Wilde; Katherine L Tucker
Journal:  Am J Clin Nutr       Date:  2009-02-18       Impact factor: 7.045

5.  Population-based analysis of Alzheimer's disease risk alleles implicates genetic interactions.

Authors:  Mark T W Ebbert; Perry G Ridge; Andrew R Wilson; Aaron R Sharp; Matthew Bailey; Maria C Norton; JoAnn T Tschanz; Ronald G Munger; Christopher D Corcoran; John S K Kauwe
Journal:  Biol Psychiatry       Date:  2013-08-13       Impact factor: 13.382

6.  Semantic network function captured by word frequency in nondemented APOE ε4 carriers.

Authors:  Jet M J Vonk; Roxanna J Flores; Dayanara Rosado; Carolyn Qian; Raquel Cabo; Josina Habegger; Karmen Louie; Elizabeth Allocco; Adam M Brickman; Jennifer J Manly
Journal:  Neuropsychology       Date:  2018-11-29       Impact factor: 3.295

Review 7.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 8.  Understanding the impact of sex and gender in Alzheimer's disease: A call to action.

Authors:  Rebecca A Nebel; Neelum T Aggarwal; Lisa L Barnes; Aimee Gallagher; Jill M Goldstein; Kejal Kantarci; Monica P Mallampalli; Elizabeth C Mormino; Laura Scott; Wai Haung Yu; Pauline M Maki; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2018-06-12       Impact factor: 21.566

Review 9.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

10.  Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment.

Authors:  Ruth A Mulnard; Marìa M Corrada; Claudia H Kawas
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.